Table 3 Associations between pill-years^a of NSAID use and invasive breast cancer by estrogen receptor (ER), progesterone receptor (PR) and HER2 status, the Sister Study (2003–2013)

 <0.75

467

1. (Ref.)

64

1. (Ref.)

56

1. (Ref.)

 0.75- < 14

156

1.05 (0.88–1.27)

15

0.72 (0.41–1.26)

26

1.40 (0.87–2.24)

 14- < 49

194

0.94 (0.79–1.11)

28

0.96 (0.61–1.51)

28

1.20 (0.76–1.90)

 ≥ 49

171

0.85 (0.7–1.01)

25

0.87 (0.54–1.4)

26

1.22 (0.75–1.97)

 P for trend

0.073

0.624

0.374

 <0.75

682

1. (Ref.)

97

1. (Ref.)

95

1. (Ref.)

 0.75- < 14

102

1.25 (1.01–1.54)

8

0.68 (0.33–1.41)

17

1.07 (0.57–2.01)

 14- < 49

118

0.89 (0.73–1.09)

16

0.85 (0.5–1.47)

22

1.43 (0.88–2.3)

 ≥ 49

86

0.97 (0.77–1.22)

11

0.9 (0.47–1.7)

11

1.15 (0.61–2.19)

 P for trend

0.569

0.501

0.261

 <0.75

890

1. (Ref.)

118

1. (Ref.)

122

1. (Ref.)

 0.75- < 21

67

1.06 (0.83–1.36)

8

0.92 (0.45–1.89)

11

1.36 (0.73–2.53)

 ≥ 21

31

0.74 (0.51–1.06)

6

1.02 (0.44–2.33)

6

1.16 (0.51–2.66)

 P for trend

0.238

0.942

0.44

 <0.75

703

1. (Ref.)

89

1. (Ref.)

93

1. (Ref.)

 0.75- < 14

112

0.93 (0.76–1.13)

19

1.17 (0.71–1.93)

21

1.25 (0.77–2.03)

 14- < 49

96

0.84 (0.68–1.05)

14

0.9 (0.51–1.59)

14

0.93 (0.53–1.63)

 ≥ 49

77

0.83 (0.65–1.05)

10

0.77 (0.4–1.5)

11

0.94 (0.44–1.77)

 P for trend

0.039

0.503

0.892